We found 1-year of treatment with EQW 2 mg resulted in significant changes to a range of AD-linked inflammatory response proteins, including CRP, sVCAM-1, FCN-2 as well as co-expressed cluster proteins (M3 and M8) scores. Here, FCN2 is linked to Alzheimer disease.